Rituximab in the treatment of rheumatoid arthritis patients in Italy: A Budget Impact Analysis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5, 2010, Pages 722-727

  Benucci, M ^a   Iannazzo, S ^b   Zaniolo, O ^b   Sabadini, L ^c  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b AdRes Health Economics and Outcomes Research   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Budget Impact Analysis; Italy; Rheumatoid arthritis; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BUDGET; BUDGET IMPACT ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; HUMAN; ITALY; MORTALITY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; SIMULATION; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HEALTH CARE COSTS; HUMANS; IMMUNOCONJUGATES; ITALY; PATIENT CARE;

EID: 78650549555     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. LEARDINI G, SALAFFI F, MONTANELLI R, GERZELI S, CANESI B: A multicenter cost-ofillness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505-15.
2. Rituximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 126. August 2007.
3. EDWARDS JCW, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
4. EDWARDS JC, CAMBRIDGE G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
5. EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSK A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, doubleblind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
6. COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
7. YAZICI Y, MCMORRIS BJ, DARKOW T, ROSEN-BLATT LC: Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2009;27:907-13.
8. BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009 Jul-Aug; 27 (Suppl. 55): S164-7.
9. WALSH CA, FEARON U, FITZGERALD O, VEALE DJ, BRESNIHAN B: Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin Exp Rheumatol 2008;26:656-8.
10. THE NATIONAL COLLABORATING CENTRE FOR CHRONIC CONDITIONS: Funded to produce guidelines for the NHS by NICE. RHEUMATOID ARTHRITIS. National clinical guideline for management and treatment in adults, http://www.nice.org.uk/ nicemedia/pdf/CG79FullGuideline.pdf. Last accessed September 2009.
11. RADSTAKE TR, SVENSON M, EIJSBOUTS AM et al.: Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
12. RUBBERT-ROTH A, FINCKH A: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11(Suppl. 1): S1.
13. KARLSSON JA, KRISTENSEN LE, KAP-ETANOVIC MC, GÜLFE A, SAXNE T, GEBOREK P: Treatment response to a second or third TNF inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:507-13.
14. GOMEZ-REINO JJ, CARMONA L: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8: R29.
15. KISHIMOTO M, GREENBERG J, ABRAMSON SB et al: Drug survival time on anti-TNF agents: does prior anti-TNF use influence RA outcomes?. Arthritis Rheum 2005;52:347.
16. FINCKH A, CIUREA A, BRULHART L et al.: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
17. FINCKH A, CIUREA A, BRULHART L et al.: Which subgroup of rheumatoid arthritis patients benefit most from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agents?. Ann Rheum Dis 2009. Epub ahead of print.
18. QUARTUCCIO L, FABRIS M, SALVIN S et al: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1557-9
19. MAUSKOPF J, SULLIVAN S, ANNEMANS L et al.: Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices-Budget Impact Analysis. Value Health 2007;10:336-47.
20. BENUCCI M, IANNAZZO S, SABADINI L: Analisi di budget impact dell'utilizzo di rituximab nel trattamento dell'artrite reumatoide in Italia. Farmeconomia e Percorsi Terapeutici 2009;10:19-31.
21. th Annual European Congress. 2008. Athens.
22. BJÖRNÅDAL L, BAECKLUND E, YIN L, GRANATH F, KLARESKOG L, EKBOM A: Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002;29:906-12.
23. ISTAT-Italian National Institute of Statistics. Mortality tables. Table 11.16. 2004.
24. MAROTTO D, NIEDDU ME, COSSU A, CAR-CASSI A: Prevalence of rheumatoid arthritis in North Sardinia: the Tempio Pausania's study. Reumatismo 2005;57:273-6.
25. ISTAT-Italian National Institute of Statistics. Population as of 1st January 2008.
26. SALAFFI F, DE ANGELIS R, GRASSI W: Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAP-PING study. Clin Exp Rheumatol 2005;23:819-28.
27. ITALIAN DRUG FORMULARY: Informatore Farmaceutico, 69a edizione. Elsevier Masson, 2009.
28. ATZENI F, SARZI-PUTTINI P: Early rheumatoid arthritis. Reumatismo 2007;59:100-17.
29. FAVALLI EG, MARCHESONI A, COLOMBO GL, SINIGAGLIA L: Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008;26:45-51.
30. RUBIO-TERRES C, ORDOVÁS BAINES JP, PLA POBLADOR R: Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp 2007;31:78-92.
31. LAUNOIS R, PAYET S, SAIDENBERG-KERMANA C'H N, FRANCESCONI C, FRANÇA LR, BOISSIER M: Budget impact model of rituximab after failure of one or more TNF-alpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008;75:688-95.
32. KOBELT G, EBERHARDT K, GEBOREK P: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.